Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.

Kapp K, Schneider J, Schneider L, Gollinge N, Jänsch S, Schroff M, Wittig B, Kleuss C.

Immun Inflamm Dis. 2016 Oct 18;4(4):446-462. eCollection 2016 Dec.


Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways.

Wu J, Su W, Powner MB, Liu J, Copland DA, Fruttiger M, Madeddu P, Dick AD, Liu L.

Sci Rep. 2016 Aug 25;6:31873. doi: 10.1038/srep31873.


TLR2, TLR4 and TLR9 genotypes and haplotypes in the susceptibility to and clinical course of Chlamydia trachomatis infections in Dutch women.

Verweij SP, Karimi O, Pleijster J, Lyons JM, de Vries HJ, Land JA, Morré SA, Ouburg S.

Pathog Dis. 2016 Feb;74(1):ftv107. doi: 10.1093/femspd/ftv107. Epub 2015 Nov 13.


VaccineDA: Prediction, design and genome-wide screening of oligodeoxynucleotide-based vaccine adjuvants.

Nagpal G, Gupta S, Chaudhary K, Dhanda SK, Prakash S, Raghava GP.

Sci Rep. 2015 Jul 27;5:12478. doi: 10.1038/srep12478.


Systematic CpT (ApG) depletion and CpG excess are unique genomic signatures of large DNA viruses infecting invertebrates.

Upadhyay M, Sharma N, Vivekanandan P.

PLoS One. 2014 Nov 4;9(11):e111793. doi: 10.1371/journal.pone.0111793. eCollection 2014.


The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum).

Byadgi O, Puteri D, Lee JW, Chang TC, Lee YH, Chu CY, Cheng TC.

J Immunol Res. 2014;2014:273284. doi: 10.1155/2014/273284. Epub 2014 Jun 2.


Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes.

Cheng WK, Wee K, Kollmann TR, Dutz JP.

Clin Vaccine Immunol. 2014 Mar;21(3):329-39. doi: 10.1128/CVI.00734-13. Epub 2014 Jan 3.


Potential capacity of aptamers to trigger immune activation in human blood.

Avci-Adali M, Steinle H, Michel T, Schlensak C, Wendel HP.

PLoS One. 2013 Jul 23;8(7):e68810. doi: 10.1371/journal.pone.0068810. Print 2013.


Spontaneous production of immunoglobulin M in human epithelial cancer cells.

Hu F, Zhang L, Zheng J, Zhao L, Huang J, Shao W, Liao Q, Ma T, Geng L, Yin CC, Qiu X.

PLoS One. 2012;7(12):e51423. doi: 10.1371/journal.pone.0051423. Epub 2012 Dec 12.


Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2013 Jan 3;121(1):136-47. doi: 10.1182/blood-2012-01-407742. Epub 2012 Nov 19.


Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes.

Yasuda K, Richez C, Uccellini MB, Richards RJ, Bonegio RG, Akira S, Monestier M, Corley RB, Viglianti GA, Marshak-Rothstein A, Rifkin IR.

J Immunol. 2009 Sep 1;183(5):3109-17. doi: 10.4049/jimmunol.0900399. Epub 2009 Jul 31.


Toll-like receptor 9-dependent activation of myeloid dendritic cells by Deoxynucleic acids from Candida albicans.

Miyazato A, Nakamura K, Yamamoto N, Mora-Montes HM, Tanaka M, Abe Y, Tanno D, Inden K, Gang X, Ishii K, Takeda K, Akira S, Saijo S, Iwakura Y, Adachi Y, Ohno N, Mitsutake K, Gow NA, Kaku M, Kawakami K.

Infect Immun. 2009 Jul;77(7):3056-64. doi: 10.1128/IAI.00840-08. Epub 2009 May 11.


Oligonucleotides suppress PKB/Akt and act as superinductors of apoptosis in human keratinocytes.

Kippenberger S, Müller J, Schultz M, Dorn A, Bock A, Aygün H, Thaçi D, Hofmann M, Kaufmann R, Bernd A.

Nucleic Acids Res. 2009 Jul;37(12):3850-64. doi: 10.1093/nar/gkp252. Epub 2009 Apr 22.


Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.

Cooper CL, Ahluwalia NK, Efler SM, Vollmer J, Krieg AM, Davis HL.

J Immune Based Ther Vaccines. 2008 Jun 9;6:3. doi: 10.1186/1476-8518-6-3.


Conditional immortalization of human B cells by CD40 ligation.

Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, Zeidler R, Moosmann A.

PLoS One. 2008 Jan 23;3(1):e1464. doi: 10.1371/journal.pone.0001464.


Development of TLR9 agonists for cancer therapy.

Krieg AM.

J Clin Invest. 2007 May;117(5):1184-94. Review.


Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals.

Martinson JA, Tenorio AR, Montoya CJ, Al-Harthi L, Gichinga CN, Krieg AM, Baum LL, Landay AL.

Immunology. 2007 Apr;120(4):526-35.


Extended sequence preferences for oligodeoxyribonucleotide activity.

Lenert P, Goeken AJ, Ashman RF.

Immunology. 2006 Apr;117(4):474-81.


Supplemental Content

Support Center